Literature DB >> 16601933

Recurrent cerebrovascular ischaemic events in patients with interatrial septal abnormalities: a follow-up study.

P Cerrato1, L Priano, D Imperiale, G Bosco, E Destefanis, A M Villar, M Ribezzo, G P Trevi, B Bergamasco, F Orzan.   

Abstract

The aim of this study was to evaluate the risk of recurrent ischaemic cerebrovascular events (stroke or transient ischaemic attack (TIA)) in patients with patent foramen ovale (PFO) or atrial septal aneurysm (ASA) treated with different therapeutic regimens. We enrolled 86 patients aged 18-60 years with an unexplained ischaemic stroke or TIA referred to our inpatient department in the period May 1994-December 1999. Follow-up lasted until April 2003. Patients were excluded if the stroke or TIA was related to large-artery atherosclerosis, small artery occlusion, major cardiac sources of embolism or other uncommon causes. During a follow-up (mean+/-SD) of 64.1+/-28.8 months (range 8.1-105.6) a recurrent ischaemic cerebrovascular event occurred in 11/86 patients (12.8%) (5 TIA and 6 strokes). Eight events (4 TIA, 4 strokes) occurred in the 59 patients with PFO alone, three (1 TIA, 2 strokes) in the 21 with PFO plus ASA and none in the 6 patients with ASA alone. In the overall population the cumulative risk of recurrent stroke/TIA was 1.2% at 2 years, 5.5% at 4 years, 7.6% at 6 years and 23.6% at 8 years, and was similar in patients with PFO alone vs. patients with PFO plus ASA (9.0% vs. 6.1% at 6 years, 26.0% vs. 23.1% at 8 years; p>0.05). Nine cerebral ischaemic events (4 TIA, 5 strokes) occurred in the 48 patients treated with antiplatelet drugs (7 in patients with PFO, 2 in patients with PFO plus ASA), and two (1 TIA, 1 stroke) in the 17 patients treated with oral anticoagulants (1 with PFO, 1 with PFO plus ASA). No events occurred in patients submitted to transcatheteral closure.

Entities:  

Mesh:

Year:  2006        PMID: 16601933     DOI: 10.1007/s10072-006-0524-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  6 in total

Review 1.  Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence.

Authors:  Georgios D Kitsios; Issa J Dahabreh; Abd Moain Abu Dabrh; David E Thaler; David M Kent
Journal:  Stroke       Date:  2011-12-15       Impact factor: 7.914

2.  PFO Closure for Cryptogenic Stroke: Review of New Data and Results.

Authors:  Shyam Rao; Cathy Sila
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

3.  Patent foramen ovale closure for patients with cryptogenic stroke: A systematic review and comprehensive meta-analysis of 5 randomized controlled trials and 14 observational studies.

Authors:  Xi Chen; Shi-Dong Chen; Yi Dong; Qiang Dong
Journal:  CNS Neurosci Ther       Date:  2018-05-27       Impact factor: 5.243

Review 4.  Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis.

Authors:  David M Kent; Issa J Dahabreh; Robin Ruthazer; Anthony J Furlan; Christian Weimar; Joaquín Serena; Bernhard Meier; Heinrich P Mattle; Emanuele Di Angelantonio; Maurizio Paciaroni; Herwig Schuchlenz; Shunichi Homma; Jennifer S Lutz; David E Thaler
Journal:  Eur Heart J       Date:  2015-07-03       Impact factor: 29.983

5.  Effect of ASA on the risk of cerebrovascular ischemic events in patients with PFO.

Authors:  Liang Xu; Chang Zhou; Xuemei Pan; Jun Zhou; Heng Sun; Tao Xu
Journal:  Ann Clin Transl Neurol       Date:  2022-07-27       Impact factor: 5.430

6.  EC-IC bypass: the failure of a clinical trial? Applicability to PFO closure trials.

Authors:  Nancy Futrell
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.